[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Hillel Yaffe Medical Center\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":256},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,39,56,78,110,131,152,174,210,235],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":16,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":24,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100603320","pediatric-patients-who-leave-the-emergency-department-without-treatment-100603320",false,"NCT07134985","Pediatric Patients Who Leave the Emergency Department Without Treatment","Inclusion Criteria:\n\n* Children aged 0-17 who arrived at the pediatric emergency department between January 2024 and December 2025.\n\nExclusion Criteria:\n\n* None","ALL","17 Years",{"count":18,"type":19},33000,"ESTIMATED","OBSERVATIONAL","Research Objectives:\n\nTo examine the clinical, operational, and demographic characteristics that influence the decision of patients to voluntarily leave the pediatric emergency department at Hillel Yaffe Medical Center before completing the evaluation or medical treatment.",[23],"Leaving Without Being Seen or Treated",[25],"Left Without Being Seen or Treated","RECRUITING","2026-04-06",{"date":29,"type":30},"2026-04-09","ACTUAL",{"date":32,"type":30},"2026-01-01",{"date":34,"type":19},"2027-12-01",{"name":36,"class":37},"Hillel Yaffe Medical Center","OTHER_GOV",1,{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":43,"acronym":4,"eligibilityCriteria":44,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":45,"enrollmentInfo":46,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":48,"conditions":49,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":51,"startDateStruct":52,"completionDateStruct":53,"leadSponsor":55,"locationsCount":38},"100587346","regional-analgesia-at-the-pediatric-emergency-department-100587346","NCT06927193","Regional Analgesia at the Pediatric Emergency Department","Inclusion Criteria:\n\n* Children who visited the pediatric emergency department between 2023-2025 and underwent a nerve block during their visit.\n\nExclusion Criteria:\n\n* Children who visited the emergency department but had the nerve block performed outside the emargency department setting (e.g., inpatient wards or operationg room), or if the block was performed by a physician not affiliated with the pediatric emergency department.","18 Years",{"count":47,"type":19},400,"Approximately two years ago, ultrasound-guided regional blocks technique was introduced into routine use in the pediatric emergency department at Hillel Yaffe Medical Center. Since then, nearly 300 different blocks have been performed.\n\nStudy Objective: To collect a registry database of complication rates associated with regional analgesia during routine pediatric emergency department care between 2023 and 2025.",[50],"Regional Anaesthesia",{"date":29,"type":30},{"date":32,"type":30},{"date":54,"type":19},"2027-01-01",{"name":36,"class":37},{"id":57,"slug":58,"hasResults":11,"nctId":59,"briefTitle":60,"officialTitle":60,"acronym":4,"eligibilityCriteria":61,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":62,"enrollmentInfo":63,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":65,"conditions":66,"keywords":68,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":77,"locationsCount":38},"100565505","cahnge-in-management-of-suspected-early-onset-neonetal-sepsis-after-assimilation-of-early-onset-sepsis-calculator-100565505","NCT06643052","Cahnge in Management of Suspected Early Onset Neonetal Sepsis After Assimilation of Early Onset Sepsis Calculator","Inclusion Criteria:\n\n* Newborn unfants born in Hillel Yaffe medical center\n* 35 weeks of gestation or more\n* Blood culture was taken\n\nExclusion Criteria:\n\n* Sepsis workup for other reason\n* 34 weeks of gestation or less","7 Days",{"count":64,"type":19},6300,"Early neonatal sepsis requires rapid and efficient intervention to prevent morbidity and mortality. Management of such a case includes invasive blood examinations, elongation of maternal and neonatal length of stay, and empiric antibiotic therapy. These actions has major side effects. On 2017, Kaiser-Permanente started using a calculator that weighs the chances for early onset neonatal sepsis, and states the best investigation and follow-up regimn for the specific newborn infant. Eversince, policy of managing neonatal suspected early onset sepsis has chaged globally, including in Israel. Current knowledge regarding the local outcome since the use of the calculatir is scarce.\n\nThe goal of the study is to evaluate the change in management of suspected neonatal early onset sepsis, including its economic value, between periods before and after assimilation of the calculator in Hillel Yaffe nedica l center.",[67],"Neonatal Early-onset Sepsis",[69,70],"Neonatal early onset sepsis","Kaiser Permanente calculator","NOT_YET_RECRUITING",{"date":73,"type":30},"2026-04-07",{"date":75,"type":19},"2026-12-01",{"date":34,"type":19},{"name":36,"class":37},{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":84,"minAge":45,"maxAge":85,"enrollmentInfo":86,"targetDuration":4,"studyType":88,"phases":89,"briefSummary":91,"conditions":92,"keywords":96,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":4},"100621839","the-effect-of-chocolate-consumption-during-labor-on-second-stage-duration-100621839","NCT07375836","The Effect of Chocolate Consumption During Labor on Second Stage Duration","Inclusion Criteria:\n\n1. Gestational age ≥37 weeks\n2. Single fetus in cephalic presentation\n3. Spontaneous or induced labor in the active phase (dilation ≥ 5 cm).\n4. Normal assessment of the mother and fetus upon admission to the delivery room (normal indices, normal monitoring and biophysical profile)\n5. BMI 18-35 -\n\nExclusion Criteria:\n\n1. Multiple pregnancies\n2. Gestational age \\\u003C37 weeks\n3. Gestational or pre-gestational diabetes\n4. Significant underlying diseases\n5. Previous cesarean section\u002Fmyomectomy\n6. Known significant fetal malformation\n7. Sensitivity to chocolate ingredients\n8. Lack of documentation of necessary information -","FEMALE","50 Years",{"count":87,"type":19},180,"INTERVENTIONAL",[90],"NA","Childbirth is an energy-intensive physiological process, requiring sustained effort comparable in intensity to moderate physical activity. Studies suggest that providing an available energy source during labor, such as dextrose infusion or natural carbohydrate-rich foods such as dates, may shorten the duration of labor and improve cervical dilation without adversely affecting obstetric outcomes. The primary objective of the study is to examine whether giving chocolate during labor affects the duration of the second stage of labor, compared to a control group that will not receive a nutritional intervention. The study is a prospective, randomized, controlled trial that will be conducted in the delivery room of Hillel Yaffe Medical Center. Healthy pregnant women with a singleton pregnancy at ≥37 weeks gestational age, in spontaneous or induced labor, without diabetes (pre\u002Fgestational), will be recruited to participate. Participants in the intervention group will receive one serving of 50 grams of milk chocolate (cocoa content 25-30%, without filling or additives) at a cervical dilation of 6 cm or more (and not yet fully dilated). The mother will be asked to consume the serving gradually over 30 minutes. Milk chocolate was chosen because it is better tolerated compared to dark chocolate, has a more gentle profile of active ingredients (which can increase nausea and heartburn) and provides a source of available carbohydrates. The study will be conducted in accordance with the guidelines of the Ministry of Health's procedure for medical experiments on humans, and will be conducted after approval by the Institutional Helsinki Committee.",[93,94,95],"Labor","Second Stage of Labor","Pregnancy",[97,98,99,100,95,93,101],"Second stage of labor","Oral carbohydrate intake","Non-pharmacologic intervention","Maternal exhaustion","Randomized controlled trial","2026-02-01",{"date":104,"type":30},"2026-02-04",{"date":106,"type":19},"2026-02",{"date":108,"type":19},"2027-01",{"name":36,"class":37},{"id":111,"slug":112,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":114,"acronym":4,"eligibilityCriteria":115,"healthyVolunteers":116,"sex":84,"minAge":45,"maxAge":85,"enrollmentInfo":117,"targetDuration":4,"studyType":88,"phases":119,"briefSummary":120,"conditions":121,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":38},"100611230","use-of-papaverine-to-shorten-the-second-stageduration-of-labor-in-pregnant-women-after-cervical-ripening-by-double-balloon-catheter-100611230","NCT07237880","Use of Papaverine to Shorten the Second Stage\u002FDuration of Labor in Pregnant Women After Cervical Ripening by Double-balloon Catheter","Inclusion Criteria:\n\n* Pregnant individuals aged 18-50 years\n* Singleton pregnancy\n* Gestational age 37-42 weeks\n* Admission for induction of labor with a double-balloon catheter\n* Planned vaginal delivery\n* Ability to provide informed consent\n\nExclusion Criteria:\n\n* Previous cesarean delivery\n* Multiple gestation\n* Contraindication to vaginal delivery\n* Known hypersensitivity to papaverine\n* Known major fetal anomaly\n* Any condition requiring immediate delivery or precluding safe participation (as determined by the treating physician)",true,{"count":118,"type":19},184,[90],"This prospective, randomized, double-blind controlled trial aims to evaluate whether intravenous papaverine, administered immediately after the removal of a double-balloon catheter used for cervical ripening, can shorten the duration of labor in term pregnant women undergoing induction of labor. Papaverine is an antispasmodic medication that relaxes smooth muscle and is commonly used in obstetrics, although its effect on labor progression following mechanical cervical ripening has not been fully studied.\n\nEligible participants include nulliparous and multiparous women with a singleton pregnancy at 37-42 weeks, admitted for induction of labor with a double-balloon catheter. After catheter removal, participants will be randomized in a 1:1 ratio to receive either 80 mg intravenous papaverine or placebo (normal saline), administered by the midwife who is not involved in clinical decision-making. Clinical staff and participants will remain blinded to group allocation.\n\nThe primary outcomes are the time from drug administration to complete cervical dilation and the duration of the second stage of labor. Secondary outcomes include mode of delivery, maternal complications (such as perineal tears and postpartum hemorrhage), oxytocin augmentation duration and maximum dose, and neonatal outcomes.\n\nThis study seeks to determine whether papaverine can safely and effectively reduce labor duration following mechanical cervical ripening.",[122],"Labor, Induced","2026-01-04",{"date":125,"type":30},"2026-01-06",{"date":127,"type":30},"2025-04-22",{"date":129,"type":19},"2027-04-22",{"name":36,"class":37},{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":4,"eligibilityCriteria":137,"healthyVolunteers":116,"sex":84,"minAge":45,"maxAge":138,"enrollmentInfo":139,"targetDuration":4,"studyType":88,"phases":141,"briefSummary":142,"conditions":143,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":38},"100617570","the-aim-of-the-study-is-to-examine-the-variation-in-blood-pressure-between-an-optimal-measurement-according-to-established-guidelines-in-the-literature---per-guidelines-and-a-common-measurement-used-by-nursing-teams---per-common-practice-among-women-of-reproductive-age-with-and-without-hyperte-100617570","NCT07320339","The Aim of the Study is to Examine the Variation in Blood Pressure Between an Optimal Measurement (According to Established Guidelines in the Literature - Per Guidelines) and a 'Common' Measurement (Used by Nursing Teams - Per Common Practice) Among Women of Reproductive Age With and Without Hyperte","Standard vs. Routine Blood Pressure Measurement in Pregnancy: Effects of Position and Diurnal Variation","Inclusion Criteria:\n\n* Women aged 18-40\n* Informed consent to participate.\n\nExclusion Criteria:\n\n* Inability to cooperate with BP measurement under optimal conditions\n* Women with complex underlying disease that may bias the data (e.g. significant vasculopathy)","40 Years",{"count":140,"type":19},500,[90],"The aim of the study is to examine the variation in blood pressure between an optimal measurement (according to established guidelines in the literature - per guidelines) and a 'common' measurement (used by nursing teams - per common practice) among women of reproductive age with and without hyperte",[144],"Blood Pressure Measurement in Pregnancy","2025-12-21",{"date":125,"type":30},{"date":148,"type":30},"2025-08-24",{"date":150,"type":19},"2026-08-24",{"name":36,"class":37},{"id":153,"slug":154,"hasResults":11,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":4,"eligibilityCriteria":158,"healthyVolunteers":116,"sex":84,"minAge":45,"maxAge":85,"enrollmentInfo":159,"targetDuration":4,"studyType":88,"phases":161,"briefSummary":162,"conditions":163,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":38},"100592347","characterization-of-placental-diffusion-100592347","NCT06992245","Characterization of Placental Diffusion","Characterization of Placental Diffusion in Women With Diabetes Using DW-MRI","Inclusion Criteria:\n\n* Women with PGAM (Pre-gestational diabetes) diagnosed before 20 weeks of pregnancy\n* Women with GDMA (Gestational diabetes) diagnosed by OGTT after 20 weeks of pregnancy\n\nExclusion Criteria:\n\n* pregnant women with placental hypoxia disease related in the past\n* pregnant women with placental hypoxia disease related in the present\n* non-singleton pregnancy\n* women in active labor or rupture of membrane\n* smoking women\n* suspicion of placenta accreta",{"count":160,"type":19},40,[90],"DW-MRI Allows a quantitative comparison of diffusion as an expression of tissue hypoxia. The investigators aim is to compare changes in placental diffusion in pregnant women with uncontrolled diabetes compared to healthy pregnant women using DW-MRI.\n\nThe investigators hypothesize that placentas of diabetic mothers will show lower diffusion \u002F perfusion compared to placentas of healthy women.",[164,165],"Pregnancy in Diabetic","Placenta Diseases","2025-12-18",{"date":168,"type":30},"2025-12-24",{"date":170,"type":30},"2023-07-06",{"date":172,"type":19},"2027-12",{"name":36,"class":37},{"id":175,"slug":176,"hasResults":11,"nctId":177,"briefTitle":178,"officialTitle":179,"acronym":180,"eligibilityCriteria":181,"healthyVolunteers":11,"sex":15,"minAge":182,"maxAge":183,"enrollmentInfo":184,"targetDuration":4,"studyType":88,"phases":186,"briefSummary":187,"conditions":188,"keywords":190,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":203,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":38},"100610895","home-based-language-and-cognitive-intervention-for-arab-toddlers-in-israel-100610895","NCT07233525","Home-Based Language and Cognitive Intervention for Arab Toddlers in Israel","Culturally Adapted Home-Based Intervention to Improve Language and Cognitive Development in Arab Toddlers in Israel: A Randomised Controlled Trial","CAHBI-T","Inclusion Criteria:\n\n* Age 18-36 months\n* Birth weight ≥1500 g\n* No significant sensory impairments or severe medical conditions\n* CAT-CLAMS scores at the lower end of the normative range (approximately -1 to 1.5 SD below mean)\n* Caregiver willing to participate in eight home sessions\n* Caregiver without moderate or severe depressive symptoms (PHQ-9 \\\u003C 10)","18 Months","36 Months",{"count":185,"type":19},240,[90],"This study evaluates the effectiveness of a culturally adapted, home-based program designed to improve language and cognitive development in Arab toddlers in Israel. Families with children aged 18-36 months will participate in eight weekly sessions delivered in their homes. The intervention teaches parents strategies to enhance their child's language, communication, and problem-solving through play, daily routines, and story time. A comparison group will receive eight sessions on child health promotion (nutrition, sleep, safety, etc.). Child outcomes will be assessed using the Clinical Adaptive Test\u002FClinical Linguistic and Auditory Milestone Scale (CAT-CLAMS) and the Arabic Communicative Development Inventories (CDI). This research aims to provide an evidence-based, scalable model for early childhood interventions in disadvantaged populations.",[189],"Enhancing Early Language and Cognitive Development in Toddlers Through a Culturally Adapted Home-based Parent Intervention",[191,192,193,194,195,196,197,198,199,200,201],"Early childhood intervention","Home-based intervention","Language development","Cognitive development","Developmental delay","Parents responsiveness","Low SES intervention","ecological","CAT-CLAMS","Communicative Development Inventories (CDI)","Arabic","2025-11-14",{"date":204,"type":30},"2025-11-18",{"date":206,"type":19},"2025-11-20",{"date":208,"type":19},"2026-12-31",{"name":36,"class":37},{"id":211,"slug":212,"hasResults":11,"nctId":213,"briefTitle":214,"officialTitle":215,"acronym":216,"eligibilityCriteria":217,"healthyVolunteers":11,"sex":84,"minAge":218,"maxAge":219,"enrollmentInfo":220,"targetDuration":4,"studyType":88,"phases":222,"briefSummary":223,"conditions":224,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":228,"startDateStruct":230,"completionDateStruct":232,"leadSponsor":234,"locationsCount":38},"100594839","clinical-and-molecular-study-to-evaluate-the-effect-of-the-pixel-co2-laser-femilifttm-for-the-treatment-of-vulvo-vaginal-atrophy-100594839","NCT07024667","Clinical and Molecular Study to Evaluate the Effect of the Pixel CO2 Laser (FemiLiftTM) for the Treatment of Vulvo-Vaginal Atrophy","Clinical and Molecular Study to Evaluate the Effect of the Pixel CO2 Laser (FemiLiftTM) for the Treatment of Vulvo-Vaginal Atrophy (VVA)","VVA PAP POPQ","Inclusion Criteria:\n\n1. Female 45-75 years of age, at the time of enrolment.\n2. Provided written informed consent.\n3. Spontaneous induced menopause as defined by one of the followings:\n\n   * Amenorrhea of ≥12 months\n   * After bilateral oophorectomy\n   * FSH levels\\>30 IU\n4. One or more VVA related symptoms (i.e., itching, dryness, burning, pain, dyspareunia, or dysuria), after other possible causes of these complaints have been excluded.\n5. Characteristic atrophic changes (see above) on gynaecological examination.\n6. Normal Papanicolaou (PAP) smear test from the last 3-5 years: if needed and as indicated according to the Israeli guidelines.\n7. Negative urine analysis test - urine stick.\n8. Asymptomatic for bacterial or fungal vaginitis.\n9. Vaginal canal, introitus and vestibule free of injuries and bleeding.\n10. Able and willing to comply with the treatment\u002F follow-up schedule and requirements.\n11. Normal general gynecological exam from the last year including US.\n\nExclusion Criteria:\n\n1. Vaginal Health Index Score (VHIS) \\\u003C 5.\n2. Active genital infection.\n3. Vaginal bleeding which did not underwent evaluation.\n4. Previous vulvar, vaginal or cervical dysplasia, within the last 2 years, or previous cancer.\n5. Recurring urinary tract infection or recurring infection of genital herpes (≥ 3 episodes in the recent year).\n6. Pelvic Organ prolapse (POP) \\>II, according to the pelvic organ prolapse quantification system (POP-Q).\n7. Serious systemic disease or any chronic condition that could interfere with study compliance.\n8. Any local, systemic and\u002For chronic autoimmune infection.\n9. Taken part in a clinical trial concerning VVA, within 30 days prior to the enrolment.\n10. Allergy to lidocaine or tetracaine.\n11. Genital skin disease that may interfere with the treatment (these subjects should be included\u002Fexcluded according to the investigator's discretion).\n12. Use of anticoagulants, within 5 days prior to enrolment.\n13. Active positive HPV test.\n14. Active positive HSV (Acute or actively present within the last 2 months).\n15. Heavy smoker (\\>1 pack of cigarettes a day)\n16. Any disease or medication that may interfere with the wound healing\u002Fimmune function.\n17. Pregnancy \u002F breast feeding.\n18. Any other reason that, in the opinion of the investigator, prevents the subject from participating in the study or compromise the subject safety.","45 Years","75 Years",{"count":221,"type":19},20,[90],"Vulvo Vaginal Atrophy (VVA) refers to the changes in the vaginal and vulvar surfaces that occurs during menopause due to the progressive loss of estrogen. The low levels of circulating estrogen produce a wide variety of anatomic, physiologic, and clinical changes in the urogenital area. Clinical symptoms include vaginal dryness, irritation, soreness, dyspareunia, dysuria, and vaginal discharge.\n\nIn recent years, microablative fractional CO2 laser has become available for treating vaginal atrophy. It showed a regenerative property with significant histological changes in cellular and connective tissue components. Treatment with the fractional CO2 laser resulted in restoration of the vaginal epithelium with ultrastructural findings, similar to a premenopausal state, that included thickened stratified squamous epithelium with increased collagen support, increased glycogen in epithelial cells, increased fibroblasts, increased vascularity, and presence of sub-epithelial papillae.",[225,226],"Vulvar Atrophy","Vaginal Atrophy","2025-06-09",{"date":229,"type":30},"2025-06-17",{"date":231,"type":30},"2022-09-02",{"date":233,"type":19},"2027-12-31",{"name":36,"class":37},{"id":236,"slug":237,"hasResults":11,"nctId":238,"briefTitle":239,"officialTitle":240,"acronym":4,"eligibilityCriteria":241,"healthyVolunteers":11,"sex":84,"minAge":45,"maxAge":242,"enrollmentInfo":243,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":245,"conditions":246,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":250,"startDateStruct":252,"completionDateStruct":254,"leadSponsor":255,"locationsCount":38},"100590748","endometrioma-ethanol-sclerotherapy---prospective-cohort-study-protocol-100590748","NCT06971458","Endometrioma Ethanol Sclerotherapy - Prospective Cohort Study Protocol","Endometrioma Ethanol Sclerotherapy and Its Effect on Ovarian Function and Fertility Treatment Outcome - Prospective Cohort Study Protocol","Inclusion Criteria:\n\nA woman with endometrioma with a diameter of 25-100 mm\n\nExclusion Criteria:\n\n* Other causes of infertility (sperm disorder, ovulation disorder, uterine disorder, mechanical factor, poor ovarian reserve)","41 Years",{"count":244,"type":19},120,"Ovarian endometriomas are cystic masses lined with endometrial tissue that contains fluid arising from a collection of menstrual debris. Ovarian endometriomas clinical manifestations includes pelvic pain, dysmenorrhea, dysfunctional uterine bleeding, and infertility.\n\nEndometriomas are most commonly treated either medically or by surgical excision.\n\nUltrasonography (US)-guided aspiration and sclerotherapy is a new approach. Its mechanism of action is believed to be destruction of the inner epithelial lining, which is followed by inflammation and fibrosis, eventually resulting in regression of the cyst. The main advantage in this approach is the avoidance of collateral damage to the ovary.",[247,248],"IVF","Endometrioma","2025-05-06",{"date":251,"type":30},"2025-05-14",{"date":253,"type":30},"2022-08-09",{"date":233,"type":19},{"name":36,"class":37},""]